We are live on
!
Find out more
IHAM
Integral Health Asset Management Portfolio holdings
AUM
$2.09B
1-Year Est. Return
112.84%
This Fund
S&P 500
This Quarter
Est. Return
-11.79%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$227M
AUM Growth
-$29.8M
(-12%)
Cap. Flow
+$9.22M
Cap. Flow
% of AUM
4.06%
Top 10 Holdings %
Top 10 Hldgs %
39.83%
Holding
81
New
31
Increased
12
Reduced
7
Closed
30
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$10.7M |
| 2 |
AstraZeneca
AZN
|
+$8.94M |
| 3 |
Encompass Health
EHC
|
+$8.33M |
| 4 |
CTLT
CATALENT, INC.
CTLT
|
+$8.19M |
| 5 |
Danaher
DHR
|
+$7.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Agilent Technologies
A
|
+$14.5M |
| 2 |
DexCom
DXCM
|
+$13.1M |
| 3 |
AMED
Amedisys
AMED
|
+$10.8M |
| 4 |
Sanofi
SNY
|
+$9.54M |
| 5 |
VAR
Varian Medical Systems, Inc.
VAR
|
+$8.52M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 88.54% |
| 2 | Energy | 3.09% |
| 3 | Consumer Discretionary | 1.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Medtronic
MDT
$110B
| $10.4M | 4.57% |
115,000
+10,000
| +10% | +$1.06M |
|
2
Centene
CNC
$31.7B
| $10.1M | 4.45% |
170,000
+45,000
| +36% | +$2.73M |
|
|
3
Merck
MRK
$317B
| $10M | 4.41% |
+136,240
| New | +$10.7M |
|
4
Bristol-Myers Squibb
BMY
$131B
| $9.76M | 4.3% |
175,000
-15,000
| -8% | -$917K |
|
5
Quest Diagnostics
DGX
$26.3B
| $9.64M | 4.24% |
120,000
+40,000
| +50% | +$4.14M |
|
6
BioMarin Pharmaceuticals
BMRN
$11.9B
| $9.29M | 4.09% |
110,000
| – | – |
|
|
7
AstraZeneca
AZN
$250B
| $8.48M | 3.74% |
+95,000
| New | +$8.94M |
|
|
CTLT
8
DELISTED
CATALENT, INC.
CTLT
| $7.79M | 3.43% |
+150,000
| New | +$8.19M |
|
|
CCXI
9
DELISTED
ChemoCentryx, Inc.
CCXI
| $7.63M | 3.36% |
190,000
+140,000
| +280% | +$5.94M |
|
|
10
Encompass Health
EHC
$12.4B
| $7.36M | 3.24% |
+144,555
| New | +$8.33M |
|
|
LHCG
11
DELISTED
LHC Group LLC
LHCG
| $7.01M | 3.09% |
+50,000
| New | +$6.96M |
|
|
12
Danaher
DHR
$141B
| $6.92M | 3.05% |
+56,400
| New | +$7.6M |
|
|
GWPH
13
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $6.57M | 2.89% |
75,000
+55,000
| +275% | +$5.82M |
|
|
MASI
14
DELISTED
Masimo
MASI
| $6.2M | 2.73% |
+35,000
| New | +$6M |
|
15
Novartis
NVS
$293B
| $5.77M | 2.54% |
+70,000
| New | +$6.25M |
|
16
Becton Dickinson
BDX
$48.8B
| $5.74M | 2.53% |
+25,625
| New | +$6.33M |
|
17
Agios Pharmaceuticals
AGIO
$1.91B
| $5.32M | 2.34% |
150,000
-40,000
| -21% | -$1.85M |
|
|
SAGE
18
DELISTED
Sage Therapeutics
SAGE
| $4.88M | 2.15% |
170,000
+50,000
| +42% | +$2.9M |
|
|
EXAS
19
DELISTED
Exact Sciences
EXAS
| $4.64M | 2.04% |
+80,000
| New | +$6.49M |
|
|
ARNA
20
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $4.62M | 2.04% |
110,000
+40,000
| +57% | +$1.83M |
|
21
Boston Scientific
BSX
$71.4B
| $4.08M | 1.8% |
125,000
-75,000
| -38% | -$2.93M |
|
|
NVRO
22
DELISTED
NEVRO CORP.
NVRO
| $4M | 1.76% |
+40,000
| New | +$4.81M |
|
23
Dentsply Sirona
XRAY
$2.64B
| $3.88M | 1.71% |
+100,000
| New | +$5.1M |
|
24
Cytokinetics
CYTK
$11B
| $3.77M | 1.66% |
+320,000
| New | +$4.08M |
|
25
Chewy
CHWY
$9.59B
| $3.75M | 1.65% |
+100,000
| New | +$2.94M |
|
Similar funds
CL
ACM
NSCM
ACG
NSUP
TP
ACP
TA
Integral Health Asset Management's Q1 2020 Portfolio in Review
As of Q1 2020, Integral Health Asset Management held 81 positions worth $227M, down 12% from $257M the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Integral Health Asset Management deployed $9.22M of net new capital in Q1 2020, opening 31 new positions and adding to 12 existing holdings. Its largest new stake was Merck: 136,240 shares worth $10M.
By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 93% a quarter earlier, followed by Energy and Consumer Discretionary.
On the sell side, the largest reduction was Humana, an estimated $6.07M trimmed.
- Integral Health Asset Management's largest Q1 2020 buy was Merck: 136,240 shares worth $10M.
- Integral Health Asset Management added most to ChemoCentryx, Inc. in Q1 2020, an estimated $5.94M increase.
- Integral Health Asset Management's biggest Q1 2020 reduction was Humana, cutting an estimated $6.07M.
- Integral Health Asset Management fully exited Agilent Technologies in Q1 2020, selling an estimated $14.5M.
- Integral Health Asset Management's ten largest holdings make up 40% of its $227M portfolio in Q1 2020.
- Integral Health Asset Management opened 31 new positions and closed 30 in Q1 2020.
- Integral Health Asset Management's portfolio value fell 12% quarter-over-quarter to $227M.
Based on Integral Health Asset Management's 13F filing for Q1 2020, filed 15 May 2020.